Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 1 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Ibex Biosciences Inc. has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are assigned to 3 distinct examiners but are all located within 1 distinct art unit. Busiest examiner FAUST, AMBER KATHLEEN is responsible for 1 pending office action. The concentration in 1 distinct art unit suggests a focused technical area despite the involvement of 3 distinct examiners.
For practitioners, the fact that 3 distinct examiners are working within the same art unit means that while individual preferences vary, the technical standards should remain consistent. Because FAUST, AMBER KATHLEEN only handles one of the 3 pending office actions, the workload is evenly split. This requires the company to maintain three separate examiner relationships while focusing on the specific guidelines of the 1 distinct art unit.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| §112 only | 1 (33%) |
| No statute on record | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FAUST, AMBER KATHLEEN | 1 | 61.1% | +53.6% |
| KELLY, ROBERT M | 1 | 74.1% | +24.1% |
| DENT, ALANA HARRIS | 1 | 44.1% | +32.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18937709 | ANTIBODIES AND THERAPEUTIC USES THEREOF | FAUST, AMBER KATHLEEN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18347295 | ANTIBODIES TARGETED TO CD147 | DENT, ALANA HARRIS | 28d overdue |
| 18937709 | ANTIBODIES AND THERAPEUTIC USES THEREOF | FAUST, AMBER KATHLEEN | — |
| 18626391 | USE OF PCBP1 TO TREAT HYPERPROLIFERATIVE DISEASE | KELLY, ROBERT M | — |
| Art Unit | Apps |
|---|---|
| 1643 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18937709 | ANTIBODIES AND THERAPEUTIC USES THEREOF | FAUST, AMBER KATHLEEN | 1643 | §101DP | Non-Final OA | — | Pending | Nov 05, 2024 |
| 18626391 | USE OF PCBP1 TO TREAT HYPERPROLIFERATIVE DISEASE | KELLY, ROBERT M | — | Other | Non-Final OA | — | Pending | Apr 04, 2024 |
| 18347295 | ANTIBODIES TARGETED TO CD147 | DENT, ALANA HARRIS | 1643 | §112 | Final Rejection | 28d overdue | Pending | Jul 05, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialIbex Biosciences Inc. has 3 pending office actions as of October 2026, spread across 1 art units and 3 examiners.
Amber Kathleen Faust has the most, with 1 of Ibex Biosciences Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
